Question 1

What are the potential benefits of participating in this trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Proof-of-concept for the Aldosterone Synthase Inhibitor LCI699 in Patients With Primary Hyperaldosteronism clinical trial (NCT00732771). Contact the study team or your healthcare provider for specific answers.

Question 2

How does LCI699 compare to my current treatment?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Proof-of-concept for the Aldosterone Synthase Inhibitor LCI699 in Patients With Primary Hyperaldosteronism clinical trial (NCT00732771). Contact the study team or your healthcare provider for specific answers.

Question 3

What side effects should I be aware of while taking LCI699?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Proof-of-concept for the Aldosterone Synthase Inhibitor LCI699 in Patients With Primary Hyperaldosteronism clinical trial (NCT00732771). Contact the study team or your healthcare provider for specific answers.

Question 4

How often would I need to visit the clinic if I participate?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Proof-of-concept for the Aldosterone Synthase Inhibitor LCI699 in Patients With Primary Hyperaldosteronism clinical trial (NCT00732771). Contact the study team or your healthcare provider for specific answers.

Question 5

What tests or monitoring would be involved during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Proof-of-concept for the Aldosterone Synthase Inhibitor LCI699 in Patients With Primary Hyperaldosteronism clinical trial (NCT00732771). Contact the study team or your healthcare provider for specific answers.

Question 6

Are there any costs associated with participating in this trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Proof-of-concept for the Aldosterone Synthase Inhibitor LCI699 in Patients With Primary Hyperaldosteronism clinical trial (NCT00732771). Contact the study team or your healthcare provider for specific answers.

What this study is about